Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Anti-IL-5 antibody reduces the increase of CD34+ eosinophils in a mouse model of airway allergic eosinophilia Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
Development of a mouse model of airway inflammation and remodeling in experimental asthma Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007
Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
Murine models of asthma Source: Eur Respir J 2003; 22: 374-382 Year: 2003
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013
Corticosteroids prevent airway remodeling in a mouse model of chronic asthma through TGF-β signaling Source: Eur Respir J 2006; 28: Suppl. 50, 225s Year: 2006
MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
CAT-354, an IL-13-neutralising human monoclonal antibody, inhibits airways hyperresponsiveness and eosinophilia in a cynomolgus monkey model of allergen challenge Source: Eur Respir J 2005; 26: Suppl. 49, 232s Year: 2005
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Pulmonary immunoglobulin E levels and the response to anti-immunoglobulin E antibody therapy in paediatric severe therapy resistant asthma Source: Annual Congress 2012 - Treating childhood asthma Year: 2012
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Source: Eur Respir Rev 2008; 17: 1-9 Year: 2008